Precigen, Inc. (NASDAQ:PGEN) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lessened its position in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) by 65.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 424,900 shares of the biotechnology company's stock after selling 792,731 shares during the period. D. E. Shaw & Co. Inc. owned about 0.15% of Precigen worth $476,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in Precigen during the fourth quarter worth approximately $27,000. Envestnet Asset Management Inc. increased its holdings in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 5,915 shares during the period. Boothbay Fund Management LLC purchased a new stake in Precigen in the 4th quarter valued at $35,000. RPO LLC acquired a new stake in Precigen during the 4th quarter worth $47,000. Finally, Invesco Ltd. increased its stake in Precigen by 14.6% in the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 6,040 shares during the period. Hedge funds and other institutional investors own 33.51% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on PGEN. HC Wainwright restated a "buy" rating and issued a $6.00 price target on shares of Precigen in a research report on Thursday, March 20th. Cantor Fitzgerald restated an "overweight" rating on shares of Precigen in a research report on Thursday, May 15th. Finally, Wall Street Zen downgraded shares of Precigen from a "hold" rating to a "sell" rating in a report on Saturday, May 24th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Precigen Stock Performance

PGEN traded down $0.08 on Friday, hitting $1.32. 508,305 shares of the company were exchanged, compared to its average volume of 1,334,666. Precigen, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $2.17. The firm has a market capitalization of $388.16 million, a P/E ratio of -2.39 and a beta of 1.82. The business's fifty day moving average is $1.42 and its 200 day moving average is $1.33.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.34 million during the quarter, compared to the consensus estimate of $0.50 million. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. Analysts forecast that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.